Topic: checkpoint inhibitors
BMS has been waiting years to get a crack at the previously untreated NSCLC market, but the end to its waiting may finally be in sight.
Pfizer and Merck KGaA’s Bavencio has so far lagged behind its classmates, in part thanks to failed studies. This time, though, it’s turned in a win.
Roche has faced criticism that the diagnostic used to ID trial patients might have swayed Tecentriq's lung cancer results. Not so, an analysis says.
Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.
As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.
Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.
BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.
After watching from the sidelines as its rivals dove into I-O’s most coveted market, AstraZeneca finally has a win in previously untreated NSCLC.
It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.